JP2006306848A - Copper compound-incorporated composition for liquid preparation for internal use - Google Patents

Copper compound-incorporated composition for liquid preparation for internal use Download PDF

Info

Publication number
JP2006306848A
JP2006306848A JP2006086911A JP2006086911A JP2006306848A JP 2006306848 A JP2006306848 A JP 2006306848A JP 2006086911 A JP2006086911 A JP 2006086911A JP 2006086911 A JP2006086911 A JP 2006086911A JP 2006306848 A JP2006306848 A JP 2006306848A
Authority
JP
Japan
Prior art keywords
copper
acid
amino acids
internal use
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006086911A
Other languages
Japanese (ja)
Other versions
JP5167594B2 (en
Inventor
Takuto Takei
拓人 武井
Kazuo Hasegawa
和夫 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP2006086911A priority Critical patent/JP5167594B2/en
Publication of JP2006306848A publication Critical patent/JP2006306848A/en
Application granted granted Critical
Publication of JP5167594B2 publication Critical patent/JP5167594B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a copper compound-incorporated composition for liquid preparation for internal use reduced in copper ion-derived astringency, easy to drink, and also leaving unpleasant aftertaste. <P>SOLUTION: The composition for liquid preparation for internal use is obtained by incorporating a copper compound and specific amino acid(s)(one or more kinds selected from the group consisting of acidic amino acid and amide thereof, basic amino acid and γ-aminobutyric acid and salts thereof). <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、銅化合物の不快な味を低減し、服用感を良好にした銅化合物配合内服液用組成物に関し、医薬及び食品の分野に利用できるものである。   [Technical Field] The present invention relates to a composition for internal use of a copper compound that reduces the unpleasant taste of a copper compound and improves the feeling of taking, and can be used in the fields of medicine and food.

銅化合物を配合した内服液剤は銅イオンに由来する不快な味のため飲みにくいものであった。この味は、タンニンやミョウバンなどのタンパクと結合する収斂剤を口にしたときの味(収斂味)と共通のものである。   An internal liquid preparation containing a copper compound was difficult to drink due to an unpleasant taste derived from copper ions. This taste is the same as the taste when using an astringent that binds to proteins such as tannin and alum.

これまで、銅化合物の不快な味を改善するため、オレオレジンやアクセント香料を配合する技術が開示されている(特許文献1)。   Until now, in order to improve the unpleasant taste of a copper compound, the technique of mix | blending an oleoresin and an accent fragrance | flavor is disclosed (patent document 1).

しかしながら、これらでは銅イオンに由来する不快な味を改善する効果は充分でなかった。   However, these are not sufficient in improving the unpleasant taste derived from copper ions.

特許第2580648号Patent No. 2580648

本発明の目的は、銅イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない銅化合物配合内服液用組成物を提供することである。   An object of the present invention is to provide a composition for internal use of a copper compound that reduces the astringent taste derived from copper ions, is easy to drink, and does not leave an unpleasant aftertaste.

上記課題を解決するために、本発明者らは、鋭意検討を重ねた結果、銅化合物に酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ-アミノ酪酸並びにこれらの塩からなる群から選ばれる1種又は2種以上のアミノ酸(以下、特定のアミノ酸類とする)を配合することにより、銅イオンによる収斂味が改善されることを見出し、本発明を完成した。   In order to solve the above-mentioned problems, the present inventors have made extensive studies, and as a result, the copper compound is selected from the group consisting of acidic amino acids and amides thereof, basic amino acids, γ-aminobutyric acid and salts thereof. Or it discovered that the astringent taste by a copper ion was improved by mix | blending 2 or more types of amino acids (henceforth a specific amino acid), and completed this invention.

本発明は、かかる知見に基づいて完成したものであり、以下の発明が包含される。
(1)銅化合物と、酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ−アミノ酢酸並びにこれらの塩からなる群から選ばれる1種又は2種以上のアミノ酸とを配合すると共に、pHが2.5〜7.0であることを特徴とする内服液用組成物。
(2)銅化合物が、グルコン酸銅、硫酸銅、クエン酸銅、塩化銅、硝酸銅およびリン酸銅からなる群から選ばれた1種又は2種以上の化合物である上記(1)に記載の内服液用組成物。
(3)酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ−アミノ酢酸並びにこれらの塩よりなる群から選択される1種又は2種以上のアミノ酸を配合することを特徴とする内服液用組成物の不快な味の低減方法。
The present invention has been completed based on such findings, and includes the following inventions.
(1) A copper compound and an acidic amino acid and its amide, a basic amino acid, γ-aminoacetic acid, and one or more amino acids selected from the group consisting of these salts are blended, and the pH is 2.5. The composition for internal use liquid characterized by being -7.0.
(2) The copper compound is one or more compounds selected from the group consisting of copper gluconate, copper sulfate, copper citrate, copper chloride, copper nitrate, and copper phosphate. Composition for internal use.
(3) An oral liquid composition comprising one or more amino acids selected from the group consisting of acidic amino acids and amides thereof, basic amino acids, γ-aminoacetic acid and salts thereof. How to reduce unpleasant taste.

本発明により、銅イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない内服液用組成物を提供することができた。   INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a composition for internal use liquid that reduces the astringent taste derived from copper ions, is easy to drink, and does not leave an unpleasant aftertaste.

この内服液用組成物は、例えば、シロップ剤、ドリンク剤などの医薬品や医薬部外品を含む各種製剤及び栄養機能食品などの各種飲料に適用できる。   This composition for internal use liquid can be applied to, for example, various preparations including pharmaceuticals such as syrups and drinks and quasi-drugs, and various beverages such as nutritional functional foods.

本発明における銅化合物とは、カチオン成分として銅を含む有機酸又は無機酸との塩であり、これらの有機酸及び無機酸は無毒性のものであればよく、有機酸としては、例えばグルコン酸、クエン酸、酒石酸が挙げられ、又は、無機酸としては、例えば硫酸、塩酸、硝酸、リン酸、炭酸が挙げられる。   The copper compound in the present invention is a salt with an organic acid or inorganic acid containing copper as a cation component, and these organic acid and inorganic acid may be non-toxic, and examples of the organic acid include gluconic acid. Citric acid, tartaric acid, or inorganic acids include, for example, sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, and carbonic acid.

配合する銅化合物としては例えば、グルコン酸銅、硫酸銅、クエン酸銅、塩化銅、硝酸銅、リン酸銅等が挙げられる。これらは、単独で配合してもよく、2種以上を組み合わせて配合してもよい。   Examples of the copper compound to be blended include copper gluconate, copper sulfate, copper citrate, copper chloride, copper nitrate, and copper phosphate. These may be blended singly or in combination of two or more.

銅化合物の配合量は、これを配合する内服液用組成物の使用目的により異なる。栄養摂取量の面からは、銅イオンに換算して、一日当たり0.1〜10mgが好ましく、1日に100mLの内服液剤として摂取する場合、その銅イオン濃度は、0.0001〜0.01W/V%である。   The compounding quantity of a copper compound changes with the intended purpose of the composition for internal use liquid which mix | blends this. In terms of nutritional intake, 0.1 to 10 mg per day is preferable in terms of copper ions. When taken as a 100 mL oral liquid solution per day, the copper ion concentration is 0.0001 to 0.01 W. / V%.

本発明においては、酸性アミノ酸(アスパラギン酸、グルタミン酸など)およびそのアミド(アスパラギン、グルタミンなど)、塩基性アミノ酸(アルギニン、ヒスチジン、リジンなど)及びγ-アミノ酪酸並びにその塩(以下、適宜に「特定のアミノ酸類」という)を用いることで、所望の収斂味改善効果を得ることができる。   In the present invention, acidic amino acids (aspartic acid, glutamic acid, etc.) and their amides (asparagine, glutamine, etc.), basic amino acids (arginine, histidine, lysine, etc.), γ-aminobutyric acid and salts thereof (hereinafter referred to as “specific” as appropriate) A desired astringent taste improving effect can be obtained by using the “amino acids”.

該アミノ酸の塩としては、アミノ酸と酸(塩酸、硫酸、メタンスルホン酸など)、塩基(アンモニア、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウムなど)又は他のアミノ酸との塩が挙げられる。   The amino acid salts include salts of amino acids with acids (hydrochloric acid, sulfuric acid, methanesulfonic acid, etc.), bases (ammonia, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, etc.) or other amino acids. Can be mentioned.

本発明においては、これら特定のアミノ酸類から1種又は2種以上を選んで配合できる。   In the present invention, one or more of these specific amino acids can be selected and blended.

また、本発明におけるγ-アミノ酪酸には、合成品だけでなく、米胚芽、米糠、お茶、南瓜などの植物由来のものや、麹菌、乳酸菌、酵母、クロレラなどの微生物由来のものも使用することができる。   The γ-aminobutyric acid used in the present invention is not limited to synthetic products, but is also derived from plants such as rice germ, rice bran, tea and nanban, and those derived from microorganisms such as koji mold, lactic acid bacteria, yeast and chlorella. be able to.

銅化合物と特定のアミノ酸類との配合比が、その銅イオン1質量部に対し0.1質量部以上であれば、所望の効果をえることができるが、好ましくは1〜20000質量部、さらに好ましくは5〜10000質量部である。   If the compounding ratio of the copper compound and the specific amino acids is 0.1 parts by mass or more with respect to 1 part by mass of the copper ions, the desired effect can be obtained, but preferably 1 to 20000 parts by mass, Preferably it is 5-10000 mass parts.

本発明の内服液用組成物のpHを2.5〜7.0に調整することで所望の効果を得ることができるが、飲用のしやすさから、pH3.0〜5.5に調整することが好ましい。   Although the desired effect can be obtained by adjusting the pH of the composition for internal use liquid of the present invention to 2.5 to 7.0, it is adjusted to pH 3.0 to 5.5 for ease of drinking. It is preferable.

本内服液用組成物のpHは、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸、コハク酸などの有機酸、これら有機酸の塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を添加して調整できる。   The pH of the composition for internal use liquid includes, for example, organic acids such as citric acid, malic acid, fumaric acid, tartaric acid, lactic acid and succinic acid, salts of these organic acids, inorganic acids such as phosphoric acid and hydrochloric acid, sodium hydroxide It can adjust by adding inorganic bases, such as.

本発明の銅化合物を配合した内服液用組成物には、ビタミン類、ミネラル類、他のアミノ酸類、生薬、生薬抽出物、カフェイン、ローヤルゼリーなどを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、保存剤、甘味料などの添加物を本発明の効果を損なわない範囲で適宜に配合できる。   In the composition for internal use liquid containing the copper compound of the present invention, vitamins, minerals, other amino acids, herbal medicines, herbal extracts, caffeine, royal jelly, etc. are appropriately selected within a range not impairing the effects of the present invention. Can be blended. Moreover, additives such as antioxidants, colorants, flavors, flavoring agents, surfactants, solubilizers, preservatives, sweeteners, and the like can be appropriately blended as necessary so long as the effects of the present invention are not impaired.

本発明の銅化合物を配合した内服液用組成物を調製する方法は特に限定されるものではない。通常、各成分を適量の精製水で溶解した後、pHを調整し、残りの精製水を加えて容量調整し、必要に応じて濾過、滅菌処理することにより目的の銅化合物を配合した内服液用組成物が得られる。   The method of preparing the composition for internal use liquid which mix | blended the copper compound of this invention is not specifically limited. Usually, after dissolving each component with an appropriate amount of purified water, adjust the pH, adjust the volume by adding the remaining purified water, and filter and sterilize as needed to mix the desired copper compound. The composition for use is obtained.

以下に実施例及び試験例を挙げ、本発明をより詳しく説明する。実施例は本発明の実施の形態を具体的に示す例であり、試験例は実施例を評価した試験の例である。本発明はこれらの実施例に限定されるものではない。   Hereinafter, the present invention will be described in more detail with reference to examples and test examples. An example is an example which shows an embodiment of the invention concretely, and a test example is an example of a test which evaluated an example. The present invention is not limited to these examples.

実施例1
グルコン酸銅 0.004g
グルコン酸亜鉛 0.02g
アルギニン塩酸塩 0.20g
アスパラギン酸マグネシウム 0.25g
グルコン酸カルシウム 0.50g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
アミノエチルスルホン酸 2.00g
キシリトール 4.00g
トレハロース 5.00g
エリスリトール 5.00g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.0に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 1
Copper gluconate 0.004g
Zinc gluconate 0.02g
Arginine hydrochloride 0.20g
0.25 g of magnesium aspartate
Calcium gluconate 0.50g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 2.00g
Xylitol 4.00g
Trehalose 5.00g
Erythritol 5.00g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例2
グルコン酸銅 0.007g
グルコン酸亜鉛 0.05g
ヒスチジン塩酸塩 0.10g
アルギニン塩酸塩 0.20g
グルコン酸カルシウム 0.40g
アスパラギン酸マグネシウム 0.30g
硝酸チアミン 0.01g
リボフラビン 0.01g
塩酸ピリドキシン 0.10g
アスコルビン酸 1.00g
アミノエチルスルホン酸 1.00g
ソルビトール 4.00g
トレハロース 5.00g
キシリトール 4.00g
ステビア抽出物 0.03g
アセスルファムカリウム 0.03g
リンゴ酸 0.10g
クエン酸 0.40g
クエン酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
アップルフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.0に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 2
Copper gluconate 0.007g
Zinc gluconate 0.05g
Histidine hydrochloride 0.10g
Arginine hydrochloride 0.20g
Calcium gluconate 0.40g
Magnesium aspartate 0.30 g
0.01 g of thiamine nitrate
Riboflavin 0.01g
0.10 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 1.00g
Sorbitol 4.00g
Trehalose 5.00g
Xylitol 4.00g
Stevia extract 0.03g
Acesulfame potassium 0.03g
Malic acid 0.10g
Citric acid 0.40g
Sodium citrate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Apple flavor 0.10g
After dissolving the above components in purified water, the pH was adjusted to 4.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例3
グルコン酸銅 0.03g
グルコン酸亜鉛 0.08g
γ-アミノ酪酸 0.20g
アルギニン塩酸塩 0.20g
リボフラビン 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
シアノコバラミン 120μg
パンテノール 0.01g
ニコチン酸アミド 0.05g
アミノエチルスルホン酸 1.00g
ソルビトール 5.00g
トレハロース 2.00g
マルチトール 2.00g
クエン酸 0.40g
リンゴ酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.5に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 3
0.03 g of copper gluconate
Zinc gluconate 0.08g
γ-aminobutyric acid 0.20 g
Arginine hydrochloride 0.20g
Riboflavin 0.01g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Cyanocobalamin 120μg
Panthenol 0.01g
Nicotinamide 0.05g
Aminoethylsulfonic acid 1.00g
Sorbitol 5.00g
Trehalose 2.00g
Maltitol 2.00g
Citric acid 0.40g
Sodium malate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 4.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例4
グルコン酸銅 0.007g
グルコン酸亜鉛 0.05g
ヒスチジン塩酸塩 0.10g
アルギニン塩酸塩 0.20g
クエン酸鉄アンモニウム 0.03g
グルコン酸カルシウム 0.80g
アスパラギン酸マグネシウム 0.40g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
ニコチン酸アミド 0.10g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ブドウ糖 5.00g
難消化性デキストリン 4.00g
エリスリトール 5.00g
キシリトール 2.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
スクラロース 0.005g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 4
Copper gluconate 0.007g
Zinc gluconate 0.05g
Histidine hydrochloride 0.10g
Arginine hydrochloride 0.20g
0.03 g of ammonium iron citrate
Calcium gluconate 0.80 g
Magnesium aspartate 0.40 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Nicotinamide 0.10g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Glucose 5.00g
Indigestible dextrin 4.00 g
Erythritol 5.00g
Xylitol 2.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Sucralose 0.005g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例5
グルコン酸銅 0.03g
グルコン酸亜鉛 0.08g
γ-アミノ酪酸 0.20g
グルタミン 0.20g
アルギニン塩酸塩 0.20g
ヒスチジン塩酸塩 0.10g
クエン酸鉄アンモニウム 0.03g
グルコン酸カルシウム 0.20g
乳酸カルシウム 0.20g
アスパラギン酸ナトリウム 0.10g
アスパラギン酸マグネシウム 0.30g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.02g
塩酸ピリドキシン 0.03g
ニコチン酸アミド 0.05g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ローヤルゼリー 0.60g
ブドウ糖 5.00g
ソルビトール 5.00g
キシリトール 5.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
クエン酸 0.60g
クエン酸ナトリウム 0.10g
リン酸 0.30g
塩酸 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 5
0.03 g of copper gluconate
Zinc gluconate 0.08g
γ-aminobutyric acid 0.20 g
Glutamine 0.20g
Arginine hydrochloride 0.20g
Histidine hydrochloride 0.10g
0.03 g of ammonium iron citrate
Calcium gluconate 0.20g
Calcium lactate 0.20g
Sodium aspartate 0.10g
Magnesium aspartate 0.30 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.02g
0.03 g of pyridoxine hydrochloride
Nicotinamide 0.05g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Royal jelly 0.60g
Glucose 5.00g
Sorbitol 5.00g
Xylitol 5.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Citric acid 0.60g
Sodium citrate 0.10g
Phosphoric acid 0.30 g
Hydrochloric acid appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

試験例
Hagermanらは、溶液中のタンパク(ウシ血清アルブミン:BSA)がタンニンにより凝集し、その沈澱量はタンニンの量に比例することを報告した(J.Agric.Food.Chem.,1978,Vol.26,809-812)。本発明者らは、銅イオン溶液にBSA溶液を加えると、この溶液が懸濁し、光の透過量が減少すること、この透過量の減少が、銅イオンの濃度に相関することを見出した。
Test example
Hagerman et al. Reported that protein (bovine serum albumin: BSA) in solution was aggregated by tannin, and the amount of precipitation was proportional to the amount of tannin ( J. Agric . Food . Chem ., 1978, Vol. 26 , 809) . -812). The present inventors have found that when a BSA solution is added to a copper ion solution, the solution is suspended, the amount of light transmitted decreases, and the decrease in the amount of transmission correlates with the concentration of copper ions.

試験方法
(1)BSA溶液の調製:BSA(Sigma Chemical Co.;fraction V,fatty acid free)6gを適量の精製水に溶解し、クエン酸100mgを加え、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。
Test method (1) Preparation of BSA solution: 6 g of BSA (Sigma Chemical Co .; fraction V, fatty acid free) is dissolved in an appropriate amount of purified water, 100 mg of citric acid is added, and the pH is adjusted with NaOH solution (1 mol / L). Adjusted to 4.8 and made up to 100 mL with purified water.

(2)希釈液の調製:クエン酸100mgを適量の水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。   (2) Preparation of diluting solution: 100 mg of citric acid was dissolved in an appropriate amount of water, pH was adjusted to 4.8 with NaOH solution (1 mol / L), and purified water was adjusted to 100 mL.

(3)銅イオン溶液の調製:グルコン酸銅0.02g、0.11g及び0.18gにクエン酸0.10gを加えた。それぞれを適量の精製水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。   (3) Preparation of copper ion solution: 0.10 g of citric acid was added to 0.02 g, 0.11 g and 0.18 g of copper gluconate. Each was dissolved in an appropriate amount of purified water, adjusted to pH 4.8 with NaOH solution (1 mol / L), and made up to 100 mL with purified water.

(4)タンパク−銅イオン相互作用(収斂性)の評価
各銅イオン溶液2mLにBSA溶液6mLを加え、希釈液でそれぞれ全量を10mLとした。これを40℃で30分間振とうした。石英セル(L=1cm)を使用し、分光光度計(日立製作所製:U−3300)により、各透明溶液では吸収されない波長である500nmにおける吸光度を測定した。この結果(図1)は、銅イオン濃度と吸光度が相関することを示す。
(4) Evaluation of protein-copper ion interaction (convergence) 6 mL of BSA solution was added to 2 mL of each copper ion solution, and the total volume was adjusted to 10 mL with a diluted solution. This was shaken at 40 ° C. for 30 minutes. Using a quartz cell (L = 1 cm), the absorbance at 500 nm, which is a wavelength that is not absorbed by each transparent solution, was measured with a spectrophotometer (manufactured by Hitachi, Ltd .: U-3300). This result (FIG. 1) shows that the copper ion concentration and the absorbance are correlated.

実際に各種濃度の銅イオン溶液の収斂味を官能評価したときの結果が、当該銅イオン溶液にBSA溶液を加えたときの吸光度と相関していることを確認した。官能評価は、収斂味が強く許容できない場合をB、許容することができる範囲をその収斂味の強さに応じてA4〜A1とし、収斂味を全く感じない場合をAとして行った。その結果を図2に示した。   It was confirmed that the results of sensory evaluation of the astringent taste of copper ion solutions having various concentrations were correlated with the absorbance when the BSA solution was added to the copper ion solution. The sensory evaluation was performed as B when the astringent taste was strongly unacceptable, A4 to A1 according to the strength of the astringent taste, and A when the astringent taste was not felt at all. The results are shown in FIG.

これらのことから、ある物質を添加した銅イオン溶液をBSA溶液に混合したときの吸光度が無添加の場合と比較して減少すると、その物質の添加により、タンパク-銅イオン相互作用による凝集(収斂性)が減少したこと、すなわち収斂味が減少したことを意味する。   From these facts, when the absorbance when a copper ion solution added with a certain substance is mixed with a BSA solution decreases compared to the case where no addition is made, the addition of that substance causes the aggregation (convergence) due to protein-copper ion interaction. ) Is reduced, that is, the astringency is reduced.

(5)各種アミノ酸のタンパク凝集性
表1に示す各種アミノ酸の液剤を調製した後,上記試験方法(1)〜(4)に記載した方法により各種アミノ酸のタンパク凝集性を評価した。結果を表2に示す。表2及び図2より、酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ-アミノ酪酸には、優れたタンパク凝集の抑制作用を有し、その吸光度はほとんど収斂味を感じない範囲であることが示された。更に、実際に、酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ-アミノ酪酸について上記試験方法(4)に記載した方法に従いBSA溶液抜き検体を調製し、上述した評価基準により、6人をパネラーとして収斂味について評価し、結果を下表3に示した。表3から明らかなように、酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ-アミノ酪酸は無添加と比較し、飲みやすく、しかも不快な後味が残らないものであった。
(5) Protein Aggregation Properties of Various Amino Acids After preparing various amino acid solutions shown in Table 1, the protein aggregation properties of various amino acids were evaluated by the methods described in the above test methods (1) to (4). The results are shown in Table 2. From Table 2 and FIG. 2, it is shown that acidic amino acids and their amides, basic amino acids, and γ-aminobutyric acid have an excellent inhibitory effect on protein aggregation, and their absorbance is in a range where almost no astringency is felt. It was done. Furthermore, BSA solution-extracted specimens were actually prepared for acidic amino acids and their amides, basic amino acids, and γ-aminobutyric acid according to the method described in the above test method (4). The astringent taste was evaluated and the results are shown in Table 3 below. As is apparent from Table 3, acidic amino acids and their amides, basic amino acids, and γ-aminobutyric acid were easier to drink and did not leave an unpleasant aftertaste as compared to the case of no addition.

Figure 2006306848
Figure 2006306848

Figure 2006306848
Figure 2006306848

Figure 2006306848
Figure 2006306848

図1はタンパク凝集と銅イオン濃度の相関性を示す。FIG. 1 shows the correlation between protein aggregation and copper ion concentration. 図2は吸光度と官能評価の相関性を示す。FIG. 2 shows the correlation between absorbance and sensory evaluation.

本発明によれば、銅化合物を配合した内服液用組成物であるにも拘わらず、銅化合物の不快な味を感じることなく飲用することが可能であることから、例えば、シロップ剤、ドリンク剤等の医薬品や医薬部外品を含む各種内服液剤及び栄養機能食品などの各種飲料を提供することができる。
According to the present invention, since it is possible to drink without feeling unpleasant taste of the copper compound despite being a composition for internal use liquid containing a copper compound, for example, syrups, drinks, etc. It is possible to provide various beverages such as various internal liquid solutions and nutritional functional foods including pharmaceuticals and quasi drugs.

Claims (3)

銅化合物と、酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ−アミノ酢酸並びにこれらの塩からなる群から選ばれる1種又は2種以上のアミノ酸とを配合すると共に、pHが2.5〜7.0であることを特徴とする内服液用組成物。   The copper compound is blended with one or more amino acids selected from the group consisting of acidic amino acids and their amides, basic amino acids, γ-aminoacetic acid and salts thereof, and the pH is 2.5-7. The composition for internal use liquid characterized by being zero. 銅化合物が、グルコン酸銅、硫酸銅、クエン酸銅、塩化銅、硝酸銅およびリン酸銅からなる群から選ばれる1種又は2種以上の化合物である請求項1に記載の内服液用組成物。   The composition for internal use according to claim 1, wherein the copper compound is one or more compounds selected from the group consisting of copper gluconate, copper sulfate, copper citrate, copper chloride, copper nitrate and copper phosphate. object. 酸性アミノ酸及びそのアミド、塩基性アミノ酸、γ−アミノ酢酸並びにこれらの塩よりなる群から選ばれる1種又は2種以上のアミノ酸を配合することを特徴とする銅化合物配合内服液用組成物の不快な味の低減方法。
Discomfort of composition for internal use of copper compound, characterized in that it contains one or more amino acids selected from the group consisting of acidic amino acids and amides thereof, basic amino acids, γ-aminoacetic acid and salts thereof. Taste reduction method.
JP2006086911A 2005-03-28 2006-03-28 Composition for internal use liquid containing copper compound Active JP5167594B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006086911A JP5167594B2 (en) 2005-03-28 2006-03-28 Composition for internal use liquid containing copper compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005090390 2005-03-28
JP2005090390 2005-03-28
JP2006086911A JP5167594B2 (en) 2005-03-28 2006-03-28 Composition for internal use liquid containing copper compound

Publications (2)

Publication Number Publication Date
JP2006306848A true JP2006306848A (en) 2006-11-09
JP5167594B2 JP5167594B2 (en) 2013-03-21

Family

ID=37474140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006086911A Active JP5167594B2 (en) 2005-03-28 2006-03-28 Composition for internal use liquid containing copper compound

Country Status (1)

Country Link
JP (1) JP5167594B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012046495A (en) * 2010-07-30 2012-03-08 Taisho Pharmaceutical Co Ltd Oral liquid medicine
CN104546818A (en) * 2015-02-04 2015-04-29 澳诺(中国)制药有限公司 Pharmaceutical composition with calcium supplement and zinc supplement effects and preparation of pharmaceutical composition
WO2017030560A1 (en) * 2015-08-18 2017-02-23 Colgate-Palmolive Company Preservative system based on organic acids
JP2020005550A (en) * 2018-07-06 2020-01-16 ポッカサッポロフード&ビバレッジ株式会社 Iron-containing beverage, production method thereof, and iron taste reduction method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504822A (en) * 1994-08-23 1998-05-12 アルビオン・インターナショナル・インコーポレーテッド Amino acid chelate with improved mouthfeel
JP2000014356A (en) * 1998-04-27 2000-01-18 Yakult Honsha Co Ltd Production of gaba-containing beverage and food product
JP2000239153A (en) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd Internal medicine composition containing iron compound
JP2001314181A (en) * 2000-05-10 2001-11-13 Mi Tec:Kk Liquors containing chelate compound
WO2004050664A1 (en) * 2002-12-05 2004-06-17 Md Bioalpha Co., Ltd. Method for preparation of amino acid chelate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504822A (en) * 1994-08-23 1998-05-12 アルビオン・インターナショナル・インコーポレーテッド Amino acid chelate with improved mouthfeel
JP2000014356A (en) * 1998-04-27 2000-01-18 Yakult Honsha Co Ltd Production of gaba-containing beverage and food product
JP2000239153A (en) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd Internal medicine composition containing iron compound
JP2001314181A (en) * 2000-05-10 2001-11-13 Mi Tec:Kk Liquors containing chelate compound
WO2004050664A1 (en) * 2002-12-05 2004-06-17 Md Bioalpha Co., Ltd. Method for preparation of amino acid chelate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012005350; Biomedical Research on Trace Elements Vol.15 , No.1, 2004, pp.49-53 *
JPN6012005352; Journal of the Science of Food and Agriculture Vol.8, 1957, pp.159-168 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012046495A (en) * 2010-07-30 2012-03-08 Taisho Pharmaceutical Co Ltd Oral liquid medicine
CN104546818A (en) * 2015-02-04 2015-04-29 澳诺(中国)制药有限公司 Pharmaceutical composition with calcium supplement and zinc supplement effects and preparation of pharmaceutical composition
WO2017030560A1 (en) * 2015-08-18 2017-02-23 Colgate-Palmolive Company Preservative system based on organic acids
CN107920517A (en) * 2015-08-18 2018-04-17 高露洁-棕榄公司 Preservative system based on organic acid
AU2015406117B2 (en) * 2015-08-18 2018-12-06 Colgate-Palmolive Company Preservative system based on organic acids
US10532014B2 (en) 2015-08-18 2020-01-14 Colgate-Palmolive Company Preservative system based on organic acids
RU2711928C2 (en) * 2015-08-18 2020-01-23 Колгейт-Палмолив Компани Preserving system
EP3760043A1 (en) * 2015-08-18 2021-01-06 Colgate-Palmolive Company Preservative system based on organic acids
CN113632790A (en) * 2015-08-18 2021-11-12 高露洁-棕榄公司 Preservative system based on organic acids
JP2020005550A (en) * 2018-07-06 2020-01-16 ポッカサッポロフード&ビバレッジ株式会社 Iron-containing beverage, production method thereof, and iron taste reduction method
JP7244226B2 (en) 2018-07-06 2023-03-22 ポッカサッポロフード&ビバレッジ株式会社 Iron-containing beverage, method for producing the same, and method for reducing iron taste

Also Published As

Publication number Publication date
JP5167594B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
JP2011120479A (en) Basic amino acid-containing packaged beverage
JP5586816B2 (en) Composition containing zinc compound
JP5098198B2 (en) Copper compound composition
JP4337308B2 (en) Liquid composition
JP5044957B2 (en) Copper compound composition
JP5162812B2 (en) Zinc-containing composition for oral administration
JP4929628B2 (en) Zinc-containing oral solution
JP5167594B2 (en) Composition for internal use liquid containing copper compound
JP5546089B2 (en) Composition containing zinc compound
JP4622006B2 (en) Iron compound-containing oral solution composition
JP5181486B2 (en) Oral composition containing zinc compound
JP5011776B2 (en) Copper compound composition
JP4940492B2 (en) Iron compound combination oral solution
JP4403595B2 (en) Iron compound-containing oral solution composition
JP2007246509A (en) Oral composition compounded with copper compound
JP4929629B2 (en) Zinc-containing composition for oral administration
JP2005035979A (en) Iron compound-including internal liquid medicine composition
JP4815798B2 (en) Copper-containing composition for oral administration
JP2004315441A (en) Liquid composition for internal use containing iron compound
JP2005255653A (en) Internal liquid medicine formulated with iron compound
JP4645842B2 (en) Royal jelly-containing beverage composition
JP4645841B2 (en) Royal jelly-containing beverage composition
JP2001316246A (en) Iron compound-formulated oral liquid preparation
JP2000239154A (en) Internal medicine composition containing iron compound
JP4929589B2 (en) Copper-containing oral administration composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090319

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121210

R150 Certificate of patent or registration of utility model

Ref document number: 5167594

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160111

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250